A new life sciences company, Magnus Life Science, has been set up in Britain with £15.5 million ($25 million) in seed funding and a business model that is unique to the U.K.; the model has similarities to strategies pursued by other companies in the U.S. and some other markets over the past several years.
The funding for Magnus Life Science comes from an undisclosed private equity investor previously active in the high-tech area; it is the first life science investment made by the investor. [See Deal] Magnus Life Science also has received £11
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?